Shares of Intersect ENT Inc (NASDAQ:XENT) have received an average recommendation of “Hold” from the eleven research firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $16.30.
XENT has been the topic of several analyst reports. SVB Leerink lifted their price target on shares of Intersect ENT from $14.00 to $18.50 and gave the company a “market perform” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. lowered their price target on shares of Intersect ENT from $28.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. BTIG Research reaffirmed a “hold” rating on shares of Intersect ENT in a report on Wednesday, June 10th. Bank of America downgraded shares of Intersect ENT from a “buy” rating to an “underperform” rating and lowered their price target for the company from $28.00 to $10.00 in a report on Wednesday, April 15th. Finally, Oppenheimer initiated coverage on shares of Intersect ENT in a report on Tuesday, June 23rd. They set a “market perform” rating on the stock.
Several hedge funds have recently added to or reduced their stakes in XENT. UBS Group AG lifted its holdings in shares of Intersect ENT by 47.1% in the first quarter. UBS Group AG now owns 2,188,412 shares of the medical equipment provider’s stock worth $25,933,000 after buying an additional 701,046 shares in the last quarter. FMR LLC lifted its holdings in shares of Intersect ENT by 1,863.8% in the first quarter. FMR LLC now owns 632,451 shares of the medical equipment provider’s stock worth $20,334,000 after buying an additional 600,246 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Intersect ENT by 2,439.1% in the first quarter. JPMorgan Chase & Co. now owns 339,274 shares of the medical equipment provider’s stock worth $4,020,000 after buying an additional 325,912 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Intersect ENT in the second quarter worth $3,498,000. Finally, Two Sigma Advisers LP increased its position in Intersect ENT by 217.4% in the first quarter. Two Sigma Advisers LP now owns 252,300 shares of the medical equipment provider’s stock worth $2,990,000 after purchasing an additional 172,800 shares during the last quarter. 85.67% of the stock is currently owned by hedge funds and other institutional investors.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Monday, May 11th. The medical equipment provider reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.10). The business had revenue of $19.83 million during the quarter, compared to analysts’ expectations of $19.70 million. Intersect ENT had a negative return on equity of 43.72% and a negative net margin of 48.61%. On average, equities research analysts predict that Intersect ENT will post -1.68 EPS for the current year.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
See Also: Accumulation/Distribution
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.